Abstract:Identification of endogenous angiogenesis inhibitors has led to development of an increasingly attractive strategy for cancer therapy and other angiogenesis-driven diseases. Vascular endothelial growth inhibitor (VEGI), a potent and relatively nontoxic endogenous angiogenesis inhibitor, has been intensively studied, and this work shed new light on developing promising anti-angiogenic strategies. It is well-documented that the RGD (Arg-Gly-Asp) motif exhibits high binding affinity to integrin alpha(v)beta(3), which is abundantly expressed in cancer cells and specifically associated with angiogenesis on tumors. Here, we designed a fusion protein containing the special RGD-4C motif sequence and VEGI-192, aimed at offering more effective multiple targeting to tumor cells and tumor vasculature, and higher anti-angiogenic and antitumor efficacy. Functional tests demonstrated that the purified recombinant human RGD-VEGI-192 protein (rhRGD-VEGI-192) potently inhibited endothelial growth in vitro and suppressed neovascularization in chicken chorioallantoic membrane in vivo, to a higher degree as compared with rhVEGI-192 protein. More importantly, rhRGD-VEGI-192, but not rhVEGI-192 protein, could potentially target MDA-MB-435 breast tumor cells, significantly inhibiting growth of MDA-MB-435 cells in vitro, triggered apoptosis in MDA-MB-435 cells by activation of caspase-8 as well as caspase-3, which was mediated by activating the JNK signaling associated with upregulation of pro-apoptotic protein Puma, and consequently led to the observed significant antitumor effect in vivo against a human breast cancer xenograft. Our study indicated that the RGD-VEGI-192 fusion protein might represent a novel anti-angiogenic and antitumor strategy.

Synthesis and Antiangiogenic Properties of 2-Methoxestradiol-rgd Peptide Conjugates

RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis.

Synthesis And Biological Evaluation Of Rgd-Conjugated Mek1/2 Kinase Inhibitors For Integrin-Targeted Cancer Therapy

Synthesis of 3′-Methoxy-e-diethylstilbestrol and Its Analogs As Tumor Angiogenesis Inhibitors

Synthesis and Antiangiogenic Activities of 5-Amino-1,3-dihydro-1,3-dioxo-2h-isoindole-2-propanoic Acid Derivatives

Synthesis and preliminary evaluation of novel alkyl diamine linked bivalent β-carbolines as angiogenesis inhibitors

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Synthesis and Biological Evaluation of Glycyrrhetic Acid Derivatives As Potential VEGFR2 Inhibitors

Novel Epothilone Methyl Derivatives Inhibit HUVEC Cell Proliferation and Angiogenesis

An Rgd-Modified Endostatin-Derived Synthetic Peptide Shows Antitumor Activity In Vivo

Synthesis of RGD-aPEG-lactoside, a Potential Anti-metastasis Glycoconjugate

Synthesis of RGD Containing Peptides and Their Bioactivities.

Dual function of RGD-modified VEGI-192 for breast cancer treatment.

Synthesis and VEGF Inhibitory Activity of 16,17-Pyrazo-annulated Steroids

Synthesis and VEGF Inhibition Activities of Some Steroidal Analogues with 3-Hydroxy-5-ene Moiety

Synthesis and Biological Evaluation of Novel Alkyl Diamine Linked Bivalent Β-Carbolines As Angiogenesis Inhibitors.

Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide

Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation

Synthesis and evaluation of graveoline and graveolinine derivatives with potent anti-angiogenesis activities.

RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo

Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy